A gradual decline in testosterone is a natural part of the aging process in men. However, when testosterone falls below normal levels and when related symptoms, such as erectile dysfunction,…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…
In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…
The era of personalized medicine is already well established in oncology. Biomarker-driven targeted therapies are among the top-selling oncology products today, and the impact of molecular…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Alzheimer’s disease (AD) is one of the most common neurological conditions in the elderly and imparts considerable strain on worldwide healthcare resources. For the estimated 2 million people in…
Outpatient parenteral antimicrobial therapy (OPAT) has become a wide-spread practice in the United States. The growth of the OPAT market has been driven by its potential to reduce healthcare costs…
Last Updated 30 June 2014 The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer compelling commercial opportunities driven by considerable unmet need. The AD population is…
Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
